The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
285 - Hi, I have a study (contained in the PM) in which only 2 versions of the same drug are being compared. The PM contains baseline and last visit levels of an endpoint marker for both drugs. In a branded detail aid, am I allowed to show a graph (baseline vs. last visit) for just one of the drugs? Or do I have to show the same type of baseline vs. last visit graph for both drugs? Thanks!
-
This type of question is best answered during the review or prior to it in the context of an opinion submission. In general, the efficacy results of a controlled trial are only interpretable in the context of both the treatment arm and the control arm (along with the corresponding statistical significance). Based on the limited info I have about your scenario, I'd have to advise reflect the PM (i.e. show both versions with the corresponding stats).
